Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake

July 30, 2014

Step Edits Are the Most Likely Strategy to Drive Use of a Biosimilar Priced 30 Percent Less than the Reference Brand, According to Findings from Decision Resources Group

BURLINGTON, Mass., July 30, 2014 /PRNewswire/ — Decision Resources Group finds that the majority of surveyed pharmacy and medical directors in the United States believe that the key drivers of biosimilar market penetration will be the level of savings achievable by their managed care organizations (MCOs) and the expected lower cost to patients. Payers plan to leverage preferential reimbursement strategies for biosimilars that meet their pricing expectations in order to encourage physician prescribing of biosimilars over the reference brands; for example, if a biosimilar costs 30 percent less than its reference brand, 33 percent of surveyed U.S. payers would require step therapy with the biosimilar before the reference brand; other strategies include implementing favorable tiering and eliminating patient co-payments and co-insurance for biosimilars.


Other key findings from the Biosimilars Advisory Service report entitled U.S. and EU Payer Perspectives on Biosimilars:

    --  Biosimilars first: Interviewed European payers indicate that there is
        growing government pressure to prescribe biosimilars, exemplified by the
        "biosimilar first" polices that are emerging in Italy, Spain and France.
    --  Pharmacy-level substitution: Payers' views on biosimilar pharmacy-level
        substitution continue to evolve in response to developing legislation in
        the United States and Europe, although payers' perception of the
        suitability of pharmacy-level substitution varies based on drug class.
    --  Formulary inclusion: Biosimilars will be selectively chosen for
        formulary inclusion based on multiple factors of differentiation,
        including the strength of the clinical data supporting the biosimilar
        and the level of trust placed in the biosimilar developer.
    --  Competition from bio-betters: Innovator companies intending to offset
        losses of existing biologics under threat from biosimilar competition
        with 'bio-betters' should focus on an improvement in efficacy rather
        than improvements in dosing frequency to obtain premium pricing.

Comments from Decision Resources Group Analyst Anees Malik:

    --  "In the U.S. healthcare market, which has seen unsustainable growth in
        expenditure over the previous decade, payers are planning to drive the
        adoption of biosimilars by synergistically delivering drug budget
        savings and decreasing patient out-of-pocket expenses."
    --  "The message from payers is clear - not all biosimilars are created
        equal. There will be winners and losers. For biosimilar developers,
        understanding the value payers attach to each differentiation metric
        used to determine formulary inclusion and preferential reimbursement is
        of paramount importance. Particularly as the EU experience with tenders
        has taught us, the biosimilars space can behave as a winner-takes-all

Upcoming webinar:

    --  Media members are welcome to attend our upcoming webinar based on this
        research, which will be held on Monday, August 18, 2014. For more
        information, please contact Christopher Comfort at

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus